eXoZymes Inc. (NASDAQ: EXOZ) has closed its previously announced underwritten public offering, raising gross proceeds of approximately $5.95 million. The biotechnology company, which focuses on AI-enhanced enzymes, issued 330,575 units to support its development and commercialization activities.

The offering included 34,440 units sold through the partial exercise of an over-allotment option. Each unit consisted of two shares of common stock and one warrant to purchase one additional share. The public offering price was set at $8.99 per share and $0.02 per warrant.

Offering Details

The warrants issued in the offering become exercisable one year from the issuance date at an exercise price of $11.24 per share. These warrants expire five years from the issuance date and are not currently listed on any national securities exchange. The company retains the right to redeem the warrants under specific conditions.

A provision allows for the warrant exercise price to reset to $0.001 if the company sells additional common stock or convertible securities before June 5, 2027, at a price lower than $8.99 per share.

Use of Proceeds

eXoZymes intends to allocate the net proceeds from the offering to several key areas. The primary focus will be on supporting the development and commercialization of N-trans-caffeoyltyramine (NCT). Additionally, funds will be used to advance other product opportunities, finance research and development activities, and provide working capital for general corporate purposes.

Regulatory and Advisory Details

MDB Capital acted as the sole book-running manager for the offering. The securities were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-292781), which the U.S. Securities and Exchange Commission (SEC) declared effective on January 23, 2026. A final prospectus supplement and accompanying prospectus were filed with the SEC on June 8, 2026.

eXoZymes Inc. has priced a public offering of units to raise approximately $5.33 million in gross proceeds, aiming to fund its operations in the AI-enhanced enzyme sector. The offering consists of 296,135 units, each priced at $18.00, and includes two shares of common stock and one warrant to purchase one share of common stock. The units will separate immediately upon issuance, with shares and warrants trading as separate securities. The offering is expected to close on June 9, 2026, subject to customary closing conditions.

Offering Details

The company has sold a total of 592,270 shares of common stock and 296,135 warrants through this unit structure. The underwriter has been granted a 45-day option to purchase up to 44,420 additional units at the public offering price, less underwriting discounts and commissions, to cover over-allotments. The gross proceeds of $5.33 million are calculated before deducting underwriting discounts, commissions, and estimated offering expenses.

Securities Structure

Each unit in the offering is composed of specific equity and derivative instruments designed to provide immediate separation upon issuance. The table below outlines the composition of the units sold:

The warrants allow the holder to purchase one share of common stock. The offering provides eXoZymes with capital to advance its technologies that transform feedstock into nutraceuticals and medicines.